TY - JOUR
T1 - An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
AU - Grünwald, Viktor
AU - Eberhardt, Berit
AU - Bex, Axel
AU - Flörcken, Anne
AU - Gauler, Thomas
AU - Derlin, Thorsten
AU - Panzica, Martin
AU - Dürr, Hans Roland
AU - Grötz, Knut Achim
AU - Giles, Rachel H
AU - von Falck, Christian
AU - Graser, Anno
AU - Muacevic, Alexander
AU - Staehler, Michael
N1 - Funding Information:
This Expert Consensus Document was funded by the International Kidney Cancer Coalition (IKCC). The authors thank A. Luetke (medinform, Ratekau, Germany) for editorial support on behalf of the IKCC.
Funding Information:
V.G. has participated in advisory boards for Bristol Myer Squibb (BMS), Eisai, Ipsen, Novartis, Pfizer, and Roche, has received honoraria for compensation from BMS, Eisai, Ipsen, Novartis, Pfizer, and Roche, and has received travel grants from BMS, MSD Merck, Novartis, and Pfizer. B.E. has received honoraria and/or travel grants from Pfizer. Uronauten receives no grants from the pharmaceutical industry. A.B. has participated in advisory boards for BMS, Ipsen, Novartis, Pfizer, and Roche/Genentech. A.F. has received honoraria and/or travel grants from Bayer, Ipsen, and Pfizer. R.H.G. has participated in advisory boards for Ipsen and Pfizer and has received travel grants from Ipsen and Pfizer. A.G. has received honoraria and/or travel grants from Bayer, Novartis, and Pfizer. M.S. participated in advisory boards for AVEO, BMS, Eisai, EUSA Pharma, Exelixis, Ipsen, Novartis, Peloton, Pfizer, and Roche/Genentech, has received travel grants from Bayer, BMS, Eisai, Ipsen, Novartis, and Pfizer, and has received research grants from AVEO, BMS, Eisai, Exelixis, Ipsen, Novartis, Pfizer, and Roche/Genentech. The International Kidney Cancer Coalition (IKCC) receives grants from Global Offices of Ipsen/Exelixis, Merck/MDS, BMS, Pfizer, Novartis, and Eisai. T.G., T.D., M.P., H.R.D., K.A.G., C.v.F., and A.M. declare no competing interests.
Publisher Copyright:
© 2018, Macmillan Publishers Ltd., part of Springer Nature.
PY - 2018/8
Y1 - 2018/8
N2 - Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.
AB - Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.
KW - Journal Article
KW - Review
KW - Interdisciplinary Communication
KW - Carcinoma, Renal Cell/diagnosis
KW - Humans
KW - Kidney Neoplasms/pathology
KW - Combined Modality Therapy/standards
KW - Bone Neoplasms/diagnosis
KW - Consensus
UR - http://www.scopus.com/inward/record.url?scp=85048556026&partnerID=8YFLogxK
U2 - 10.1038/s41585-018-0034-9
DO - 10.1038/s41585-018-0034-9
M3 - Review article
C2 - 29904105
SN - 1759-4812
VL - 15
SP - 511
EP - 521
JO - Nature Reviews. Urology
JF - Nature Reviews. Urology
IS - 8
ER -